1. Home
  2. PHAR vs TNDM Comparison

PHAR vs TNDM Comparison

Compare PHAR & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$12.94

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

HOLD

Current Price

$18.54

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
TNDM
Founded
1988
2006
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
PHAR
TNDM
Price
$12.94
$18.54
Analyst Decision
Strong Buy
Buy
Analyst Count
3
19
Target Price
$38.33
$28.00
AVG Volume (30 Days)
4.5K
1.5M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,014,736,000.00
Revenue This Year
$10.04
$8.11
Revenue Next Year
$2.51
$11.85
P/E Ratio
$3,041.22
N/A
Revenue Growth
N/A
7.93
52 Week Low
$10.55
$10.00
52 Week High
$21.34
$29.65

Technical Indicators

Market Signals
Indicator
PHAR
TNDM
Relative Strength Index (RSI) 38.08 61.29
Support Level $11.88 $17.79
Resistance Level $13.61 $18.23
Average True Range (ATR) 0.46 1.01
MACD -0.11 0.21
Stochastic Oscillator 3.92 93.31

Price Performance

Historical Comparison
PHAR
TNDM

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Share on Social Networks: